Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects
Portfolio Pulse from Vandana Singh
An FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals' patisiran, but raised concerns about the drug's efficacy. The FDA has set an action date of October 8, 2023. Analysts from William Blair, Needham, Stifel, and Cantor Fitzgerald provided mixed views on the approval prospects and potential label restrictions. ALNY shares are down 8.08% at $194.55.
September 14, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Alnylam's patisiran received a favorable vote from an FDA committee, but concerns about its efficacy were raised. Analysts have mixed views on the approval prospects and potential label restrictions. ALNY shares are down 8.08%.
The FDA committee's vote in favor of patisiran is a positive development for Alnylam. However, the concerns raised about the drug's efficacy and potential label restrictions could negatively impact its market potential and, consequently, Alnylam's stock price. This is reflected in the 8.08% drop in ALNY shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100